|
WO2020247648A2
|
|
Pd-1 agonist and method of using same
|
|
TW202021983A
|
|
Anti-il-33 therapy for eosinophilic asthma
|
|
WO2019183639A1
|
|
Inhibition of allergic reaction to peanut allergen using an il-33 inhibitor
|
|
WO2019074912A1
|
|
Anti-il-33 therapy for atopic dermatitis
|
|
SG10201913306WA
|
|
Antibodies directed against programmed death- 1 (pd-1)
|
|
EP3689419A1
|
|
Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
|
|
CN109475622A
|
|
Inhibit allergic reaction using IL-33 inhibitor
|
|
WO2016168542A1
|
|
Antibodies directed against interleukin 36 receptor (il-36r)
|
|
AU2016242964A1
|
|
Antibodies directed against T cell immunoglobulin and Mucin Protein 3 (TIM-3)
|
|
WO2016126858A2
|
|
Antibodies directed against lymphocyte activation gene 3 (lag-3)
|
|
US2017158762A1
|
|
Antibodies directed against discoidin domain receptor family, member 1 (ddr1)
|
|
US2016333090A1
|
|
Antibodies directed against interleukin-33 (IL-33) and methods of making and using
|
|
CA2910278A1
|
|
Antibodies directed against programmed death-1 (pd-1)
|
|
WO2014172448A2
|
|
Antibodies directed against activin receptor type ii (actrii)
|
|
US2014079691A1
|
|
Thermostable antibody framework regions
|
|
US2014056878A1
|
|
Humanized antibodies directed against complement protein C5
|
|
US2013101601A1
|
|
Antibodies directed against nerve growth factor (NGF)
|
|
US2013102031A1
|
|
Use of somatic hypermutation to create insertion and deletion mutations in vitro
|
|
NZ607615A
|
|
Antibodies directed against il-17
|
|
CA2793309A1
|
|
Method of producing transcripts using cryptic splice sites
|
